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We read, with much interest, the recently published
article byWeber et al. [1]. The authors demonstrated, using a
well-established major histocompatibility complex (MHC)-
mismatched BALB/c/B6 experimental bone marrow trans-
plantation (BMT) model, that host CD8aþ dendritic cells
(DCs) play a negative regulatory role in regulating graft-
versus-host disease (GVHD) by controlling activation of
other host DC subsets and, subsequently, through regulatory
T cells (Tregs). At the same time, Weber’s report shows that
host DCs are not required for inducing acute GVHD by using
the CD11c-iDTR mouse model. The latter data on host DCs in
acute GVHD is consistent with previous reports [2e4]. With
regards to the function of host CD8aþ DCs in GVHD, Weber
et al.’s data partially supported our recent observations [5,6].
Utilizing Batf3/ animals in an MHC-matched multiple
minor antigensemismatched BMT model (C3H.sw/B6), we
found a critical role for CD8aþ DCs in the induction of
optimal graft-versus tumor responses, but they did not
appear to increase severity of GVHD [6]. We, however, wish
to report that we had also examined whether the Batf3-
dependent CD8aþ DCs affects the pathogenesis of acute
GVHD in an MHC-disparate acute GVHD model (BALB/
c/B6). Similar to the observations in Weber’s report, our
data suggested that the deﬁciency of Batf3 in host antigen-
presenting cells exacerbates acute GVHD in an MHC-
disparate model (data not shown).Financial disclosure: See Acknowledgments on page 775.
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capable of cross-presentation, they also have an immune-
regulatory function [7] and induce immune tolerance un-
der certain circumstances. Suss et al. [8] reported that CD8aþ
DCs decrease allogeneic T cell responses when compared
with CD8a DCs in mixed lymphocyte reaction in vitro. This
result was reproduced in our own mixed lymphocyte reac-
tion assay (data not shown). In addition to Weber’s reported
data, we also demonstrated that Flt-3 ligand expanded
CD8aþ DCs, which reduced acute GVHD severity [9]. Donor T
cells vaccinated by host-type CD8aþ DCs also decreased
acute GVHD in an IL-10edependent manner [5]. CD8aþ DCs
can also induce Tregs in a TGF-b dependent manner in vitro
and in vivo, as stated in this report. Our and Weber’s data
suggest that CD8aþ DCs may play either no role or act as a
negative regulator of GVHD, depending on the intensity of
allo-reaction and the model systems. However, they none-
theless appear to be important for inducing optimal graft-
versus-leukemia (GVL) responses. Collectively, these obser-
vations suggest that it may be possible to ﬁne tune and
enhance GVL responses either without aggravating or even
mitigating GVHD.
These data thus suggest that it may be possible to start
meaningfully separating the severity of GVHD from GVL by
targeting antigen-presenting cell subsets, even if we still
can’t still completely separate the two, GVHD and GVL, after
allo-BMT.
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